Hazard ratios can be approximated by data extracted from published Kaplan–Meier curves. Recently, this curve approach has been extended beyond hazard-ratio approximation with the capability of constructing time-to-event data at the individual level. In this article, we introduce a command, ipdfc, to implement the reconstruction method to convert Kaplan–Meier curves to time-to-event data. We give examples to illustrate how to use the command.
BarlowR. E., BartholomewD. J., BremnerJ. M., and BrunkH. D.1972. Statistical Inference Under Order Restrictions: Theory and Application of Isotonic Regression.New York: Wiley.
2.
BonnerJ. A., HarariP. M., GiraltJ., AzarniaN., ShinD. M., CohenR. B., JonesC. U., SurR., RabenD., JassemJ., OveR., KiesM. S., BaselgaJ., YoussoufianH., AmellalN., RowinskyE. K., and AngK. K.2006. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine354: 567–578.
3.
DeeksJ. J., HigginsJ. P. T., and AltmanD. G.2008. Analysing data and undertaking meta-analyses. In Cochrane Handbook for Systematic Reviews of Interventions, ed. HigginsJ. P. T., and GreenS., 243–296. Chichester, UK: Wiley.
4.
FoxK. M.2003. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet362: 782–788.
5.
GuyotP., AdesA. E., OuwensM. J. N. M., and WeltonN. J.2012. Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan–Meier survival curves. BMC Medical Research Methodology12: 9.
6.
ParmarM. K. B., TorriV., and StewartL.1989. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine17: 2815–2834.
7.
PerrenT. J., SwartA. M., PfistererJ., LedermannJ. A., Pujade-LauraineE., KristensenG., CareyM. S., BealeP., CervantesA., KurzederC., du BoisA., SehouliJ., KimmigR., StähleA., CollinsonF., EssapenS., GourleyC., LortholaryA., SelleF., MirzaM. R., LeminenA., PlanteM., StarkD., QianW., ParmarM. K. B., and OzaA. M.2011. A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine365: 2484–2496.
8.
van PuttenW., and RoystonP.2017. irax: Stata module to perform isotonic regression analysis. Statistical Software Components S458406, Department of Economics, Boston College. https://ideas.repec.org/c/boc/bocode/s458406.html.
9.
RoystonP., and ParmarM. K. B.2011. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Statistics in Medicine30: 2409–2421.
10.
TierneyJ. F., StewartL. A., GhersiD., BurdettS., and SydesM. R.2007. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials8: 16.
11.
WeiY., RoystonP., TierneyJ. F., and ParmarM. K. B.2015. Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: Application to individual participant data. Statistics in Medicine34: 2881–2898.
12.
WilliamsonP. R., SmithC. T., HuttonJ. L., and MarsonA. G.2002. Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine21: 3337–3351.
